With sufficient cytotoxic lymphocyte infiltration in the tumor microenvironment, blockade of the PD-1/PD-L1 pathway by ICIs can activate effective anti-tumor immunity [28,30]. This evidence concerns the gene PDCD1 and neoplasm.